Alder Biopharmaceuticals Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes various therapeutic antibodies in the United States and Australia. It is developing monoclonal antibodies comprising ALD403, which has completed Phase Ib proof-of-concept trials to target calcitonin gene-related peptide for the prevention of migraine; and Clazakizumab that has completed Phase IIb clinical trials that inhibits the pro-inflammatory cytokine interleukin-6 in the treatment of rheumatoid arthritis and psoriatic arthritis. The company also has preclinical programs in the discovery phase for various indications. Alder Biopharmaceuticals Inc. has a collaboration with Bristol-Myers Squibb Company for the development of Clazakizumab. Alder Biopharmaceuticals Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.
Address
11804 North Creek Parkway South
BOTHELL, WA 98011
United States
BOTHELL, WA 98011
United States
Website
http://www.alderbio.comKey stats and ratios
| Q4 (Dec '13) | 2013 | |
| Net profit margin | -80.33% | -109.67% |
| Operating margin | -79.15% | -110.45% |
| EBITD margin | - | -105.48% |
| Return on average assets | -50.40% | -45.11% |
| Return on average equity | - | - |
| Employees | 77 |
No comments:
Post a Comment